Samsung’s foray into the U.S. biologic-drug market is proving tougher than expected, as the South Korean company faces strong resistance from established pharmaceutical companies while doctors and patients are reluctant to switch to biosimilars.
from WSJ.com: US Business https://on.wsj.com/2FpK5Yh
via IFTTT
No comments:
Post a Comment